

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Biostime International Holdings Limited

合生元國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1112)

UNAUDITED OPERATIONAL STATISTICS FOR THE THREE MONTHS ENDED 31 MARCH 2016

In order to provide better disclosure to investors and the shareholders of Biostime International Holdings Limited (the “Company”, together with its subsidiaries, the “Group”), the board (the “Board”) of directors (the “Directors”) of the Company wishes to announce the unaudited operational statistics of the Group for the three months ended 31 March 2016. The following are the unaudited operational statistics of the Group for the three months ended 31 March 2016, with comparative figures for the three months ended 31 March 2015:

REVENUE BY PRODUCT SEGMENT (UNAUDITED)

The unaudited consolidated revenue of the Company by product segment for the three months ended 31 March 2016 and the comparative figures for the three months ended 31 March 2015 are as follows:

	For the three months ended	
	31 March	
	2016	2015
	<i>RMB million</i>	<i>RMB million</i>
	(unaudited)	(unaudited)
Revenue by product segment		
Baby nutrition and care products	867.8	995.7
Adult nutrition and care products	601.2	404.1
Total	<u>1,469.0</u>	<u>1,399.8</u>

Note:

1. The comparative figures for the three months ended 31 March 2015 in the above table are prepared as if Swisse Wellness Group Pty Ltd had become a subsidiary of the Company before 1 January 2015.
2. For illustrative purposes, the exchange rates of AUD1= RMB4.7248 and AUD1= RMB4.8437 have been used for the preparation of the unaudited consolidated revenue of the Company for the three months ended 31 March 2016 and the comparative figures for the three months ended 31 March 2015, respectively.

In the first few months of 2016, the infant formula market in China remained competitive. During the three months ended 31 March 2016, the Group's revenue derived from the baby nutrition and care products segment declined by 12.8% as compared with that of the corresponding period in 2015. Nevertheless, according to Nielsen, an independent market research company, the Group's share of the overall infant formula market in China remained stable and increased to 6.2% for the three-month period ended 29 February 2016, from 5.9% for the corresponding period ended 28 February 2015.

As of 31 March 2016, the number of member retail outlets increased from 37,983 year on year to 39,169, among which, the number of the Group's VIP baby specialty stores increased from 26,707 to 27,759, retail sales organizations decreased from 6,918 to 6,270, and VIP pharmacies increased from 4,358 to 5,140.

During the three months ended 31 March 2016, sales of products of Swisse Wellness Group Pty Ltd ("Swisse"), a non-wholly owned subsidiary of the Company, increased by 48.8% as compared with that of the corresponding period in 2015, and Swisse maintained its leading position in the Australian vitamin, herbal and mineral supplements ("VHMS") market. Based on data from IRI Aztec, Swisse was the No. 1 brand in the Australian VHMS market and continued to gain market share, which reached 19.0% for the twelve months till the end of March 2016, up from 14.3% for the twelve months till the end of March 2015. According to data from Alibaba, in China, Swisse also maintained its No. 1 position in terms of sales in the healthcare category on both Tmall and Taobao for the three months ended 31 March 2016.

The Board wishes to remind shareholders and potential investors that the above operational statistics have not been reviewed or audited by the independent auditors of the Company. Differences may arise between such statistics and the data disclosed in audited report due to review and audit adjustment. **Shareholders and potential investors are cautioned not to unduly rely on such statistics and are advised to exercise caution in dealing in the shares of the Company.**

By Order of the Board
Biostime International Holdings Limited
Luo Fei
Chairman

Hong Kong, 8 May 2016

As at the date of this announcement, the executive Directors are Mr. Luo Fei and Mr. Radek Sali; the non-executive Directors are Dr. Zhang Wenhui, Mr. Wu Xiong, Mr. Luo Yun and Mr. Chen Fufang; and the independent non-executive Directors are Dr. Ngai Wai Fung, Mr. Tan Wee Seng and Professor Xiao Baichun.